All AbMole products are for research use only, cannot be used for human consumption.
Depatuxizumab mafodotin is an antibody-drug conjugate (ADC) which specifically targets the epidermal growth factor receptor (EGFR). Depatuxizumab mafodotin (up to 10 nM; up to 72 h) can induce cell death in glioma cell lines overexpressing EGFR or EGFRvIII. Depatuxizumab mafodotin (0-3.38 nM; 72 h) induces cell death in a dose-dependent manner in human head and neck squamous cell carcinoma (HNSCC) cell lines (UMSCC47 and FaDu) with high EGFR expression, with IC50 values of 0.213 nM and 0.167 nM for UMSCC47 and FaDu cell lines, respectively.
Immobilized EGFR-P00533-25-645-chis at 2 μg/mL (30 μL/well) can bind Depatuxizumab mafodotin with the EC50 of 19.05 ng/mL.
Depatuxizumab mafodotin (8 mg/kg; i.p.; every 4 days; 6 times in total) causes the loss of EGFRvIII expression in tumors in the orthotopic implantation model of LN-229 EGFRvIII cells in immunodeficient CD1 nude mice. Depatuxizumab mafodotin (4 mg/kg; i.p.; every 4 days; 4 times in total) significantly inhibits tumor growth in female nude mice xenografted with the FaDu cell line.
The drug-to-antibody ratio (DAR) of the Depatuxizumab mafodotin is 4.3.
| Molecular Weight | 148240 |
| CAS Number | 1585973-65-4 |
| Storage | Store at ≤ -20℃ for 24 months. Avoid repeated freeze-thaw cycles. |
| Related Antibody-Drug Conjugates (ADCs) Products |
|---|
| Oregovomab-MMAE
Oregovomab-MMAE is an antibody-drug conjugate (ADC). |
| Patritumab-MMAE
Patritumab-MMAE is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab attached to MMAE. |
| Ozuriftamab vedotin
Ozuriftamab vedotin (BA3021) is an antibody-drug conjugate (ADC), it is composed of receptor tyrosine kinase orphan receptor 2 (ROR2) humanized monoclonal antibody Ozuriftamab and VcMMAE. |
| Glembatumumab vedotin
Glembatumumab vedotin (CDX-011) is an antibody-drug conjugate (ADC) comprising a fully human IgG2 monoclonal antibody (CR011) directed against glycoprotein NMB (GPNMB) and conjugated to the potent tubulinbinding cytotoxic agent MMAE via a protease-sensitive vc linker. Glembatumumab vedotin has potent anticancer effects. |
| Denintuzumab-MMAF
Denintuzumab-MMAF is an antibody-drug conjugate (ADC). Codrituzumab is a monoclonal antibody targeting GPC3 (glypican-3). Denintuzumab (hBU 12) is a recombinant humanized anti-CD19 monoclonal antibody. Denintuzumab binds to CD19 on the surface of B cells. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
